Skip to content Skip to footer
Subscribe Now
Rhythm Pharmaceuticals
NEWS

Rhythm Pharmaceuticals Reports the US FDA Approval of Imcivree (Setmelanotide) for Acquired Hypothalamic Obesity

Shots: The US FDA has approved Imcivree for the treatment of pts (≥4yrs.) with acquired hypothalamic obesity (HO) Approval was supported by the global P-III (TRANSCEND) trial assessing setmelanotide (n=94) vs PBO (n=48) in 142 pts with acquired HO Trial met its 1EP with a 18.4% PBO-adjusted reduction in BMI, showing -15.8% vs +2.6% mean…
March 20, 2026

Read more

INSIGHTS+

Know Your Investor: Perceptive Advisors (March’25 Edition)

Shots:   The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com  With…
March 20, 2025

Read more